Viridian Therapeutics, Inc. (NASDAQ: VRDN)
$19.1700
+0.0200 ( -6.94% ) 1.2M
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
Market Data
Open
$19.1700
Previous close
$19.1500
Volume
1.2M
Market cap
$1.52B
Day range
$19.1450 - $21.3440
52 week range
$11.4000 - $27.2000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| def | Proxies and info statements | 5 | Apr 26, 2024 |
| 8-k | 8K-related | 14 | Apr 16, 2024 |
| 4 | Insider transactions | 1 | Apr 01, 2024 |
| 8-k | 8K-related | 17 | Feb 27, 2024 |
| 10-k | Annual reports | 100 | Feb 27, 2024 |
| 4 | Insider transactions | 1 | Feb 14, 2024 |
| 3 | Insider transactions | 2 | Feb 14, 2024 |
| 4 | Insider transactions | 1 | Feb 07, 2024 |
| 4 | Insider transactions | 1 | Jan 24, 2024 |
| 8-k | 8K-related | 16 | Jan 19, 2024 |